Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC—are we making progress?

Benzer Materyaller

• Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer—the Holy Grail in cancer treatment?
  Yazar:: Sellmann, Ludger, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Overall survival in non-small cell lung cancer—what is clinically meaningful?
  Yazar:: Fenchel, Klaus, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment—are we barking up the wrong tree?
  Yazar:: Dempke, Wolfram C. M., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
  Yazar:: Manz, Kirsi M., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Continuation of Tyrosine Kinase Inhibitor is Associated with Survival Benefit in NSCLC Patients with Exon 19 Deletion after Solitary Progression
  Yazar:: Na, Feifei, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)